Oxford BioDynamics signs first pharmaceutical EpiSwitch Orion agreement with Johnson & Johnson
Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.
The commercial agreement announced on 5 November 2026 will apply Oxford BioDynamics' cloud-based EpiSwitch Orion 3D-genomics technology to research seeking baseline genomic biomarkers that may predict patient response to a biologic therapy for inflammatory bowel disease.
The partnership follows an earlier academic Orion commercial agreement announced in July 2026 and represents a new pharmaceutical research application, with financial terms undisclosed and no diagnostic approval or therapeutic licensing rights announced.
Field | Content |
Article Type | Deals |
Company | Oxford BioDynamics |
Pharmaceutical Partner | Johnson & Johnson |
Deal Type | Commercial biomarker research agreement |
Announcement Date | 5 November 2026 |
Transaction Status | Agreement announced |
Technology Platform | EpiSwitch Orion |
Platform Delivery | Cloud-based |
Technology Type | 3D-genomics biomarker discovery |
Research Focus | Baseline genomic biomarkers associated with treatment response |
Therapeutic Area | Gastroenterology |
Disease Area | Inflammatory bowel disease |
Treatment Class Studied | Biologic therapy |
Specific Biologic | Not disclosed in supplied summary |
Research Objective | Identify genomic biomarkers potentially predictive of patient response to biologic treatment |
Pharmaceutical Customer | Johnson & Johnson |
Commercial Milestone | First pharmaceutical-company agreement for EpiSwitch Orion |
Previous Orion Commercial Agreement | Academic agreement announced in July 2026 |
Financial Consideration | Not disclosed |
Licensing Structure | Commercial research arrangement; detailed financial and intellectual property terms not disclosed |
Regulatory Status | No new diagnostic regulatory approval announced |
Drug Licensing Status | No new therapeutic licence announced |
Clinical Validation Status | Not established by the supplied agreement summary |
What Happened | Oxford BioDynamics signed its first pharmaceutical-company agreement for EpiSwitch Orion with Johnson & Johnson. |
Why It Matters | The agreement extends commercial use of a 3D-genomics biomarker platform into pharmaceutical research aimed at improving understanding of treatment response. |
Strategic Rationale | Apply genomic biomarker discovery technology to support precision-medicine research in inflammatory bowel disease. |
Transaction Distinction | Commercial biomarker research agreement rather than an approved diagnostic or drug licensing transaction. |
Key Takeaway | Johnson & Johnson will use EpiSwitch Orion in an inflammatory bowel disease biomarker-discovery programme. |
What to Watch | Biomarker findings, subsequent validation, expansion of pharmaceutical partnerships and potential clinical research applications. |
Primary Source | Oxford BioDynamics announcement |
Primary Source URL | https://www.investegate.co.uk/announcement/rns/oxford-biodynamics--obd/first-pharma-agreement-for-episwitch-orion/9859325 |
Relevant Date | 5 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios